Nosenzo John 4
4 · Bioventus Inc. · Filed Feb 14, 2022
Insider Transaction Report
Form 4
Nosenzo John
Chief Commercial Officer
Transactions
- Tax Payment
Class A Common Stock
2022-02-10$12.88/sh+24,205$311,760→ 42,434 total - Exercise/Conversion
Phantom Profit Units
2022-02-10−66,139→ 0 total→ Class A Common Stock (66,139 underlying) - Exercise/Conversion
Class A Common Stock
2022-02-10+66,139→ 66,639 total
Footnotes (1)
- [F1]Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering.